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Abstract
Background: Antibiotic resistance (ABR) is an urgent problem globally, with overuse and misuse of antibiotics
being one of the main drivers of antibiotic-resistant infections. There is increasing evidence that the burden of
community-acquired infections such as urinary tract infections and bloodstream infections (both susceptible and
resistant) may differ by ethnicity, although the reasons behind this relationship are not well defined. It has been
demonstrated that socioeconomic status and ethnicity are often highly correlated with each other; however, it is
not yet known whether accounting for deprivation completely explains any discrepancy seen in infection risk. There
have currently been no systematic reviews summarising the evidence for the relationship between ethnicity and
antibiotic resistance or prescribing.
Methods: This protocol will outline how we will conduct this systematic literature review and meta-analysis
investigating whether there is an association between patient ethnicity and (1) risk of antibiotic-resistant infections
or (2) levels of antibiotic prescribing in high-income countries. We will search PubMed/MEDLINE, EMBASE, Global
Health, Scopus and CINAHL using MESH terms where applicable. Two reviewers will conduct title/abstract screening,
data extraction and quality assessment independently. The Critical Appraisal Skills Programme (CASP) checklist will be
used for cohort and case-control studies, and the Cochrane collaboration’s risk of bias tool will be used for randomised
control trials, if they are included. Meta-analyses will be performed by calculating the minority ethnic group to majority
ethnic group odds ratios or risk ratios for each study and presenting an overall pooled odds ratio for the two outcomes.
The Grading of Recommendations, Assessments, Development and Evaluation (GRADE) approach will be used to assess
the overall quality of the body of evidence.
Discussion: In this systematic review and meta-analysis, we will aim to collate the available evidence of whether there is
a difference in rates of AMR and/or antibiotic prescribing in minority vs. majority ethnic groups in high-income countries.
Additionally, this review will highlight areas where more research needs to be conducted and may provide insight into
what may cause differences in this relationship, should they be seen.
Systematic review registration: PROSPERO (CRD42016051533)
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Background
Antibiotic resistance (ABR) is a serious threat to the
treatment of infections in primary and secondary care in
the UK and around the world. Optimising the use of
antibiotics is a high priority as one of the main drivers
of AMR is the misuse and overuse of antibiotics [1, 2].
This is a particular concern in high-income countries
with ready access to antibiotics, as opposed to poorer
countries where treatment of infections may be prob-
lematic due to the limited availability of these drugs [3].
There is increasing evidence that the burden of
community-acquired infectious diseases such as urinary
tract and bloodstream infections (both drug-susceptible
and drug-resistant) or colonisation with multidrug-
resistant (MDR) strains may differ by ethnicity [4–6],
although the reasons behind this relationship are not yet
clear. It has long been established that the concept of
ethnicity in relation to disease burden is not one of
biological difference as there is more genetic diversity
within ethnic groups than between them, rather it is
more relevant as a social construct [7]. It has been dem-
onstrated in many studies that socioeconomic status and
ethnicity are typically highly correlated with each other
[4, 8, 9]; however, it is not yet known whether account-
ing for deprivation completely explains any discrepancy
seen in infection risk between different communities.
Could there be other factors at play?
It is therefore important to understand firstly whether
the risk of AMR infections is disproportionately higher
in minority or majority ethnic groups in settings where
excess rather than access to antibiotics is more likely to
be a problem. Secondly, if a difference is shown to exist,
it will be key to understand why this difference is occur-
ring and how it can be addressed.
There is increasing evidence that recent travel,
particularly to South Asia (Bangladesh, India, Pakistan,
Nepal, Sri Lanka etc.) and East Asia (China, Japan,
Mongolia, Taiwan etc.), is a major risk factor for colon-
isation with drug-resistant bacteria leading to the risk of
poorer health outcomes, treatment failure and subse-
quent transmission of these bacteria upon return to the
country of residence [10, 11]. Several studies have
confirmed that travel to certain geographical areas is an
important risk factor for colonisation with extended
spectrum beta-lactamase (ESBL) Enterobacteriaceae—-
with travel to the Indian subcontinent, Asia and Africa
(north of the equator)—being areas of highest risk [12–16].
Among travellers, those particularly at risk of being colo-
nised with multidrug-resistant bacteria are those visiting
friends and family (indicating frequent travel to a particular
region) and recent migrants [16].
Another possible factor which may account for differ-
ences in ABR burden may be that the level of awareness
around appropriate antibiotic use varies with differing
population attributes. In a study by McKee et al., 192
participants from an ethnically diverse urban community
in the USA were interviewed about their health-seeking
behaviours, their use of antibiotics without a prescrip-
tion and their perception of the effectiveness of different
treatments for upper respiratory tract infections (URTIs)
[17]. The majority of participants believed that antibi-
otics were effective against URTIs, with 26% having
obtained antibiotics either directly from a pharmacist or
from a source outside the USA and 31% believed that
antibiotics should be available over the counter. Worry-
ingly, participants originally from countries where anti-
biotics were available over the counter were significantly
more likely to use antibiotics without a prescription than
those who were born in the USA or those born in coun-
tries where antibiotics were not available over the coun-
ter (p = 0.049) [17].
It is widely recognised that the knowledge, behaviour
and attitudes of both the prescriber and the patient
influence antibiotic prescribing [18]. It is therefore
essential that public knowledge and behaviour change
campaigns around the use of antibiotics reach all citi-
zens. In a UK-based study by McNulty et al. [19], a ques-
tionnaire was included in the Office of National
Statistics (ONS) Omnibus Household Survey in Britain
to ascertain the public’s knowledge about antibiotics. Of
the 7120 participants from England, Scotland and Wales,
38% did not know that antibiotics do not work on most
coughs and colds, 4.8% had used an antibiotic without
advice from a healthcare provider, 1.7% had given antibi-
otics to someone for whom they were not prescribed
and 4.7% had obtained an antibiotic in another country
without a prescription. When ethnicity was taken into
consideration, participants of Asian or Black Caribbean
ethnicity gave more responses indicating incorrect
knowledge or use of antibiotics than White British
participants [19].
There have been no systematic reviews or meta-analyses
summarising the evidence for the relationship between
ethnicity and antibiotic resistance or prescribing; this
review is therefore warranted in order to collate the avail-
able evidence. The aims for the systematic review will be
to determine if there is evidence for an association be-
tween patient ethnicity and (1) consumption of antibiotics
or (2) risk of antibiotic-resistant infections in high-income
countries. The overall aim of this paper is to outline a
transparent method for screening, collecting and collating
the data available along with describing the statistical
methodology that will be used for a meta-analysis should
the data allow for such an analysis to be conducted.
Methods/design
To improve the quality of reporting, this protocol has
been written in accordance with the Preferred Reporting
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Items for Systematic Reviews and Meta-Analyses for
Protocols (PRISMA-P) guidelines (checklist can be
found in Additional file 1). The protocol is registered
with PROSPERO (CRD42016051533).
Research questions
The following research questions were developed:
1. What evidence is there for an association between
patient ethnicity and risk of antibiotic-resistant
infections in high-income countries?
2. What evidence is there for an association between
patient ethnicity and prescribing of antibiotics in
high-income countries?
Population
All men and women of any age living in any of the 35
high-income countries will be included. A high-income
country will be defined as being a member country of
the Organisation for Economic Co-operation and Devel-
opment (OECD) high-income status group [20]. A list of
the 35 OECD-defined high-income countries can be
found in Additional file 2.
Exposure
The exposure of interest will be patient ethnicity and
will be defined by ethnicity reported in the health record
or self-reported by the patient. We are interested in
measuring the difference in rates of antibiotic resistance
or antibiotic prescribing between minority and majority
ethnic groups. The definition of “minority” and “major-
ity” ethnic groups will differ depending on the country
in which the study takes place and will be guided by
how the ethnic groups under study are reported in the
articles and verified by national census data where they
are available.
Comparator/control
The comparator will be patients falling into the “major-
ity” ethnic group in the high-income country being stud-
ied. For example, in the UK, the majority ethnic group
would be “White” whereas the minority ethnic groups
would include all “Black” ethnic backgrounds (Black or
Black British: Caribbean, African or Other Black back-
ground), all “Asian” ethnic backgrounds (Asian or Asian
British: Indian, Pakistani, Bangladeshi, Chinese or other
Asian background), all “Mixed or Multiple” ethnic back-
grounds and “Other” ethnic backgrounds [21]. In Japan,
however, the majority ethnic group would be “Japanese”
and the minority ethnic groups would be “Korean”,
“Chinese” and “American” [22].
Outcomes
The primary outcomes of the included studies will be ei-
ther infection-related outcomes or antibiotic prescribing-
related outcomes as outlined below. The reporting of ei-
ther of these outcomes will be mandatory for inclusion.
1. Infection-related outcomes
-Prevalence or incidence of antibiotic-resistant
infections defined as the number of new or existing
antibiotic-resistant infections per 1000 population (for
community rates) or per 1000 admissions or occupied
bed days (OBD) (for hospital rates).
-Percentage (%) of infections resistant to an antibiotic
class which should otherwise be effective against that
pathogen.
2. Antibiotic prescribing-related outcomes
-Prescribing or consumption of antibiotics measured as
defined daily doses (DDD) or number of items per
1000 population (for community rates) or DDD or
number of items per 1000 admissions or OBD (for
hospital rates).
Secondary outcomes of the included studies will be
the study setting (prescribing in primary care/commu-
nity-acquired infections vs. prescribing in secondary
care/hospital-acquired infections) and age (children vs.
adults). These outcomes will not be mandatory for inclu-
sion but it is expected that they will be reported in most
included studies.
Inclusion/exclusion criteria
Observational studies including cohort (retrospective
and prospective), case-control, cross-sectional, longitu-
dinal and ecological study designs conducted in high-
income countries and containing quantitative data on
antibiotic-resistant infection/colonisation or antibiotic
prescribing by ethnic group will be included. Interven-
tional studies (randomised controlled trials) will be
included if they meet the criteria in Part A; however, we
do not expect that there have to be such studies in this
area. Only articles written in or translated into English
will be included. All age groups, genders and time
periods will be included.
Studies will not be included if they are set in middle-
or low-income countries, defined as countries which are
not members of the OECD high-income status group.
All studies focussing exclusively on tuberculosis, HIV/
AIDS, malaria, viral hepatitis or sexually transmitted in-
fections such as chlamydia, syphilis or gonorrhoea will
be removed during screening as these infections have
been widely studied separately and are beyond the scope
of this review. Clinical case studies, case reports and
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systematic reviews or meta-analyses will also be
excluded during screening. Studies set in intensive care
units only or studies using entire countries as compara-
tors will be excluded. Finally, studies written in a
language other than English will be excluded.
Search strategy
The search strategy will include electronic database
searching, citation searching of the included full-text
articles and a grey literature search. The following data-
bases will be searched: MEDLINE via PubMed,
EMBASE, Global Health, Scopus and CINAHL. Refer-
ence lists of the included articles will be screened for
relevant articles not previously found in the database
searches. Grey literature will be reviewed using Google
Scholar and OpenGrey. Dissertations and theses will be
searched for in ProQuest Dissertations and Theses.
Search terms will be tailored for each database, using
MeSH terms where applicable, and will be checked by a
medical librarian to ensure the syntax is correct.
No study design or date limits will be imposed on the
search, although only studies in English will be included
due to limited resources. Medline, EMBASE and Global
Health databases will be searched through Ovid; Scopus
and CINAHL databases will be searched separately. The
specific search strategies will be created with the assist-
ance of a Health Sciences Librarian with expertise in
systematic review searching. The search terms are based
around the concepts of “ethnicity”, “antibiotic prescrib-
ing”, “antibiotic resistance” and “high-income countries”.
The “ethnicity”-related search terms have been informed
by a Cochrane review investigating culturally appropriate
health education for type 2 diabetes in minority ethnic
groups [23]. The PubMed/MEDLINE search strategy is
included in Additional file 3 as an example. These search
terms will then be adapted to the syntax and subject
headings of the other databases. The search will be
updated toward the end of the review to ensure that all
information in the review is up-to-date. The publications
from the five databases will be exported into EPPI Re-
viewer software (https://eppi.ioe.ac.uk/cms/Default.aspx?-
tabid=2914), where duplicates will be removed.
All titles and abstracts yielded by the search will be in-
dependently screened by two authors (HL for all articles
and ECS, AC, VA or VM as second reviewers) to ensure
consistency of the application of the inclusion/exclusion
criteria. Full texts will be obtained for all titles that
appear to meet the inclusion criteria and any discrepan-
cies will be resolved by discussion among the review
team or by the principal investigator. Additional infor-
mation will be sought from study authors where neces-
sary to resolve questions about eligibility. Reasons for
excluding studies will be recorded. Once full texts have
been obtained, all reviewers will perform data extraction,
HL on the entire set of included studies and ECS, AC,
VA and VM on a quarter of the studies each.
Reference lists of the included studies will be searched
for relevant articles which were missed by the original
database search. Relevant title/abstracts will be screened
against the inclusion and exclusion criteria and will be
reviewed independently by two authors in the same way
as for the database search. Full texts will be retrieved
from included articles and data will be extracted.
Grey literature will be reviewed by searching for
relevant documents in OpenGrey, Google Scholar and
ProQuest Dissertations and Theses. In OpenGrey, the
following search will be performed: ((antibiotic) OR
(antimicrobial)) AND ((ethnic*) OR (socio*)). In Google
Scholar, the following search will be performed: “anti-
biotic” AND “ethnic*” and the first 100 articles will be
reviewed. In ProQuest Dissertations and Theses, the fol-
lowing search will be performed: ab,ti(antibiotic*) AND
ab,ti(ethnic*). The documents will be screened against
the inclusion and exclusion criteria and reviewed inde-
pendently by two authors in the same way as for the
database search.
Quality assessment
The reviewers will independently assess the quality of
the included full-text articles. The quality and risk of
bias of observational studies will be assessed using the
Critical Appraisal Skills Programme (CASP) checklist for
cohort and case-control studies independently by the
review team and discussed if discrepancies occur
(www.casp-uk.net). Cross-sectional studies will be qual-
ity assessed using the Appraisal tool for Cross-Sectional
Studies (AXIS tool) [24]. If randomised control trials are
included, the Cochrane collaboration’s risk of bias tool
will be used to assess quality. A quality assessment chart
based on a traffic light system of “good”, “adequate” and
“poor” reporting will be developed as recommended by
Cochrane [25].
Data analysis and synthesis
Data extraction will be performed independently by two
reviewers using a customised form in EPPI Reviewer.
Data extracted will include first author, year of publica-
tion, year(s) of study, country, aim/hypothesis, study
design, number of participants (N), age range of partici-
pants, setting (community or hospital), urban or rural
area, individual or population level exposure, ethnic
categories for comparison, which groups are exposure
group and which are control (minority vs. majority
ethnic group in that country), outcome measured (anti-
biotic prescribing or antibiotic resistance or both), how
outcome was measured (defined daily doses (DDD)/1000
population, DDD/1000 admissions, DDD/1000 OBD, in-
cidence or prevalence of resistant infection, % resistance
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in a group etc.), unadjusted relative difference between
groups (risk ratio, odds ratio etc.), variables adjusted for
(such as age, sex, comorbidities, lifestyle factors), and
adjusted relative difference between groups.
The data synthesis will depend upon the level of het-
erogeneity of the extracted data. Heterogeneity will be
assessed by generating forest plots of the individual
included studies to examine confidence intervals, using
the χ2 test to determine whether there is evidence of sig-
nificant heterogeneity between the studies (p < 0.10) and
calculating the I2 statistic to estimate the level of hetero-
geneity using values of 30 to 60%, 50 to 90% and 75 to
100% to indicate moderate, substantial and considerable
heterogeneity, respectively [25]. Based on the outcomes
of these tests combined, if a quantitative analysis is not
possible due to the data being too heterogeneous, a
narrative synthesis will be provided to summarise the
results displayed in the included studies. This will
include providing tables and summary measures based
on the primary outcomes (prescribing and resistance
rates) stratified by the secondary outcomes (hospital vs.
community settings, children vs. adults). Due to the
broad scope of this systematic literature review, hetero-
geneity is expected with respect to study design, study
populations and the reporting of exposures (ethnicity)
and outcomes (prescribing or resistance). Separate tables
will be created for each of the two primary outcomes to
explore these factors and compare and contrast the
results of the studies within and between the subgroups
(hospital vs community and children vs adult).
-Community setting will be comprised of either
antibiotic prescribing at the general practitioner (GP)
practice (DDD or number of items per 1000
population) or incidence of antibiotic-resistant
infections presenting at the GP practice or within two
days of admission to hospital (community-associated
infections).
-Hospital setting will be comprised of either antibiotic
prescribing for an admitted patient in hospital (DDD or
number of items per 1000 OBD or admissions) or
incidence of antibiotic-resistant infections presenting at
least two days after admission to hospital (hospital-ac-
quired infections).
-Adults will be patients 18 years of age or older;
children will be patients 0–17 years of age.
Where homogenous data allow, meta-analyses will be
performed using random effect models (based on the
variables specified). Where outcomes are continuous,
they will be transformed to categorical or binary
variables as appropriate. The minority ethnic group to
majority ethnic group odds ratios for each included
study will then be calculated in a similar way to the
Ethnic Minority Meta-Analysis (EMMA) [26], and over-
all pooled odds ratios with 95% confidence intervals for
the two outcomes (and/or sub analyses) will be pre-
sented from the random effects models. Should more
than one randomised controlled trial be included, separ-
ate meta-analyses will be performed for the trials and for
the included observational studies. All analyses will be
performed in EPPI Reviewer.
Meta-bias(es) and confidence in cumulative evidence
If the number of included articles is high enough and if the
data allow, funnel plots will be used to detect the presence
of publication bias. The Grading of Recommendations,
Assessments, Development and Evaluation (GRADE) ap-
proach will be used to assess the quality of the body of evi-
dence and a summary of findings table will be used to
present the results.
Dissemination
The systematic review and meta-analysis will be submit-
ted for publication in a relevant journal. The results will
be presented at conferences that are in line with the
topic area. This work will contribute to a PhD project as
part of the National Institute for Health Research Health
Protection Research Unit (NIHR HPRU) in Healthcare-
Associated Infections and Antimicrobial resistance at
Imperial College London. The results of the review will
be communicated to public and patient populations
through the Race Equality Foundation dissemination
networks as well as through public announcements by
the HPRU.
Discussion
In this systematic review and meta-analysis, we will aim
to collate and present the available evidence of whether
there is a difference in rates of AMR and/or antibiotic
prescribing by minority vs. majority ethnic groups in
high-income countries. In this way, this review will
contribute to a wider body of knowledge of the role of
socio-demographic factors such as poverty and minority
ethnic background may play in the risk of antibiotic-
resistant infections in resource-rich countries where
excess of antibiotics is of greater concern than access.
The results of this review will describe this relationship
and highlight areas where more research needs to be
conducted and may provide insight into possible reasons
for any differential levels of risk that may be seen.
Some possible limitations of this review that can be
anticipated at this stage are (i) the English language
restriction on the included articles due to resource limi-
tations in the review team and (ii) that there are not
likely to be any articles from France as they do not rec-
ord ethnicity in the national census. These potential
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limitations will be taken into consideration when inter-
preting the findings of this review.
Additional files
Additional file 1: PRISMA-P checklist. The Preferred Reporting Items for
Systematic Reviews and Meta-Analyses for Protocols (PRISMA-P) checklist
was used to develop this protocol. (DOCX 29 kb)
Additional file 2: List of OECD high-income countries. List of countries
classified as “high income” by the Organisation for Economic Co-
operation and Development (OECD). (DOCX 12 kb)
Additional file 3: Search terms for MEDLINE. The search terms that will
be used to identify relevant literature in MEDLINE as an example,
adapted for the other four databases. (DOCX 14 kb)
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